Announced two pivotal clinical updates: HI-PEITHO (EKOS for intermediate-risk pulmonary embolism) and CHAMPION-AF (WATCHMAN FLX vs NOACs in non-valvular atrial fibrillation). HI-PEITHO met its composite primary endpoint, with EKOS plus anticoagulation superior to anticoagulation alone (4.0% vs 10.3%; P=0.005), a 61% relative reduction in events within 7 days. HI-PEITHO showed lower cardiorespiratory decompensation/collapse with EKOS (3.7% vs 10.3%) and no intracranial bleeding through 30 days; 544 patients across 59 U.S./EU sites; follow-up planned to 1 year. CHAMPION-AF (n=3,000; 141 global sites) met all primary and secondary endpoints at 36 months: non-procedural bleeding was statistically lower with WATCHMAN FLX vs NOACs (10.9% vs 19.0%; P<0.001), a 45% relative reduction. Including procedural bleeding, WATCHMAN FLX still had significantly lower major/clinically relevant non-major bleeding (12.8% vs 19.0%; P<0.001), a 34% relative reduction. Primary efficacy endpoint (stroke, cardiovascular or unexplained death, or systemic embolism) was non-inferior for WATCHMAN FLX vs NOACs (5.7% vs 4.8%; P<0.001 for non-inferiority). Secondary safety endpoint was non-inferior for major bleeding (procedural and non-procedural) at 36 months (5.9% vs 6.4%; P<0.001). A combined safety/efficacy endpoint favored WATCHMAN FLX (15.1% vs 21.8%; P<0.001), with a 99% procedural success rate; follow-up will continue to 5 years. Company plans to use CHAMPION-AF data in submissions to expand indication and coverage; both trials were presented as ACC.26 late-breakers and published in NEJM.